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Objective: We sought to calculate accumulated dose
(DA) to the rectum in patients treated with radiotherapy
for prostate cancer. We were particularly interested in
whether dose–surface maps (DSMs) provide additional
information to dose–volume histograms (DVHs).
Methods: Manual rectal contours were obtained for
kilovoltage and daily megavoltage CT scans for 10 partic-
ipants from the VoxTox study (380 scans). Daily delivered
dose recalculation was performed using a ray-tracing
algorithm. Delivered DVHs were summated to create
accumulated DVHs. The rectum was considered as a cylin-
der, cut and unfolded to produce daily delivered DSMs;
these were summated to produce accumulated DSMs.
Results: Accumulated dose-volumes were different from
planned in all participants. For one participant, all DA
levels were higher and all volumes were larger than
planned. For four participants, all DA levels were lower
and all volumes were smaller than planned. For each of
these four participants, $1% of pixels on the accumulated
DSM received $5Gy more than had been planned.
Conclusion: Differences between accumulated and planned
dose-volumes were seen in all participants. DSMs were able
to identify differences between DA and planned dose that
could not be appreciated from the DVHs. Further work is
needed to extract the dose data embedded in the DSMs.
These will be correlated with toxicity as part of the VoxTox
Programme.
Advances in knowledge: DSMs are able to identify differ-
ences between DA and planned dose that cannot be
appreciated from DVHs alone and should be incorporated
into future studies investigating links between DA and
toxicity.
INTRODUCTION
Prostate cancer is the most common cancer affecting
males in the UK, accounting for 26% of all new cases of
cancer in males in England in 2012.1 Overall survival
measured at 10 years from diagnosis is the fourth highest
of all cancers in the UK at 84%.2,3 External beam ra-
diotherapy (RT) is one of several treatment options
available to patients with non-metastatic disease.4 The
introduction of three-dimensional (3D) conformal RT in
the 1990s reduced toxicity and so enabled dose escalation
to the prostate; this translated into improved tumour
control as measured by biochemical progression in var-
ious clinical trials.5–9 This was, however, at the expense of
increased $grade 2 late gastrointestinal toxicity, seen in
each trial.7–11
Since this time, development of other technologies, such as
intensity modulation and image guidance, has enabled the
dose to normal tissues to be reduced, with consequent
improvements in toxicity.12–17 Advances in dose compu-
tation offer the potential to reduce the dose to normal
tissues even further, by adapting the dose distribution
during treatment on an individual basis. If the dose could be
reduced to critical structures then there may be opportunity for
further dose escalation to tumour. Methods to estimate this may
identify a subgroup of patients in whom safe dose escalation
could be undertaken. These approaches are likely to have ap-
plication in prostate cancer given the positional variation of the
rectum during treatment, its proximity to the tumour target and
the use of hypo-fractionated schedules.18–27
In order to be able to accurately predict normal tissue com-
plication probability (NTCP) in an individual, understanding
the precise relationship between dose and toxicity is essential.
At present, predictive models are based on “planned” dose–
volume histograms (DVHs) calculated from a single planning
CT scan before treatment.28 This does not incorporate any
measure of anatomic variation during treatment, which has
been shown to affect dose to the rectum in several
studies.19,23,24,29–31 In addition, DVHs as produced from the
treatment plan are not ideal representations of 3D doses as
they discard spatial information.28
To our knowledge, four studies in the literature have used daily
image guidance CT scans to calculate accumulated dose (DA) to
the rectum over a course of RT for prostate cancer.23,24,30,31 Two
used helical tomotherapy megavoltage (MV) scans, one used
CT-on-rails and one used MV cone-beam CT. Whilst providing
useful early data, each of these studies was limited by one or
more factors. These included: missing scans (unable to be re-
trieved), poor quality scans (in some cases the prostate was not
scanned and in some there were unacceptable artefacts), in-
adequacy of imaged rectal volumes, inspection of only one or
two dose-volume levels, and deforming planned dose dis-
tributions onto new anatomy, rather than recalculating the dose.
We sought to improve on these, by recalculating dose on daily
scans from patients treated with RT to prostate and pelvic lymph
nodes, and summating these data to produce accumulated
DVHs. We also developed dose–surface maps (DSMs) as a way
of retaining 3D dose information. These measures of DA will be
correlated with toxicity as part of the VoxTox study.32
METHODS AND MATERIALS
Ethics approval for the VoxTox study was granted on 4 February
2013. This is an observational study to collect comprehensive
toxicity data for 1500 patients undergoing image-guided intensity-
modulated radiotherapy (IMRT) to the prostate, head and neck
and central nervous system. The aim is to establish the toxicity
following treatment and how this relates to the DA to the rectum,
salivary glands and hypothalamic–pituitary axis.
Rectal contours for 10 study participants were obtained as
previously described.18 Each participant was treated using helical
tomotherapy, with intensity modulation and daily MV image
guidance and positional correction to a dose of 74Gy in 37
fractions over 7.5 weeks.33 Following training with a radiologist,
JES outlined the rectum on the kilovoltage (kV) planning scan
and daily MV image guidance scans for the 10 participants using
ProSoma® (Oncology Systems Limited, Shropshire, UK). The
entire circumference of the rectal wall was contoured on each
slice of each MV scan where it was shown. Digital imaging and
communications in medicine (DICOM) RT plans, and the
translational and rotational setup errors (X, Y, Z and roll)
identiﬁed by the radiographers for each fraction, were retrieved
from the TomoTherapy® (Accuray, Sunnyvale, CA) archive using
in-house software.34 All data were anonymized and tokenized
and then transferred from the hospital network to the University
Physics Laboratory for storage, curation and processing.
Analysis of the MV CT scans revealed that the external contour
of the body laterally was not shown in some cases. This was
due to the scan circle of the MV CT being 38.6 cm diameter,
and too small to encompass the entire patient outline. To
address this, the relevant daily shift was applied to the centre
of the MV CT, and the corresponding part of the kV image was
used for any tissue falling outside the circle. A masked kV
image was created by setting all Hounsﬁeld unit (HU) values
within the circle to 21000 (corresponding to zero density), and
merged with the MV CT. The superior rectum was present on all
MV scans; in cases where the MV scan did not extend sufﬁciently
to show the inferior rectum, contours and slices from the kV scan
were used.18
A dose calculation programme was written as a command-line
application in MATLAB® (MathWorks®, Natick, MA). This per-
formed a ray-tracing algorithm over a set of points covering the
image.35 Dose calculations were carried out at each point, using
a radiological path length calculated as the sum of those for the
MVCT image and for the masked kV image. The use of a separate
masked image, rather than one composite image, took account of
differences in pixel spacing and HU to electron density con-
versions between the scans. For MV scans, the HU to electron
density conversion varied slightly with the date of image acqui-
sition. We have measured this using a “cheese phantom” with
density inserts as part of the monthly quality assurance checks
over a seven-year period. The appropriate conversion was used for
each MV scan; this depended on the date of the scan and which of
our two TomoTherapy machines was used. The calculated dose
cube was saved as a DICOM RT dose object. The superior rectum
was present on all MV scans; in cases where the MV scan did not
extend sufﬁciently to show the inferior rectum, contours and
slices from the kV scan were used.18
Daily “delivered” DVHs were produced for each participant;
these were summated to produce “accumulated” DVHs. Vol-
umes of rectum receiving 20, 30, 40, 50, 60, 65, 70 and 75Gy,
and doses to 80%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 25%,
15%, 5% and 3% of the rectum, were compared with those
planned. Accumulated generalized equivalent uniform doses
(gEUDs) were calculated using a5 11.11 as per quantitative
analyses of normal tissue effects in the clinic (QUANTEC).36
The doses and volumes chosen comprised the constraints from
two recent trials.37,38
Planned and daily delivered DSMs were produced based on
algorithms described by Murray et al39 and Buettner et al.40 The
rectum was considered as a cylinder and dose was sampled at
points on each CT slice. The cylinder was “cut” at the point
where a vertical line from the centroid of each contour crossed
the posterior edge and unfolded (Figure 1).
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Each pixel on a DSM comprised a horizontal (posterior–
posterior) coordinate and a vertical (superior–inferior) co-
ordinate, with the doses at these points displayed. To obtain the
horizontal coordinates, the rectal circumference was measured
on the outline for each CT slice and divided by 20. Coordinates
were then determined as 21 equally spaced points around the
circumference with the ﬁrst and 21st being at the cut point. For
the vertical coordinates, we used the longitudinal coordinates of
the kV CT slices. The dose at each of these points was then
determined by interpolation into the calculated dose matrix.
Accumulated DSMs were constructed by summating the pixels
from the delivered DSMs. For participants where the inferior
rectum was not shown on any MV scans, this part of the ac-
cumulated DSM appeared identical to the planned DSM. To
avoid this, in Figures 2 and 3 we have greyed out all slices where
none of the MV slices extended sufﬁciently. Each pixel from the
planned DSM was then subtracted from the equivalent pixel
from the accumulated DSM to produce a “difference” DSM for
each participant. These were inspected to assess whether they
provided additional information above that from the DVHs.
To facilitate visual comparison of the DSMs, we developed a system
to standardize their superior–inferior lengths. The median MV ra-
dius during treatment was calculated for each participant as pre-
viously described.18 The mean of this value and the corresponding
kV radius was used to calculate a rectal circumference for each
participant. The circumference was then divided into 20 equal parts,
each corresponding to the width of a square pixel on the DSM. For
each participant, the superior–inferior kV rectal length was divided
by the pixel size. The median of the results for the 10 participants
was used as the superior–inferior length of the DSMs.
RESULTS
The accumulated gEUD was different from the planned gEUD in
all 10 participants (median 22.7Gy, range 210.2 to 15.3 Gy),
and lower in 7 of the 10; full results are shown in Table 1. DVHs
for the participant with the highest accumulated compared with
planned gEUD (Participant A) are shown in Figure 4; DVHs for
the participant with the lowest accumulated compared with
planned gEUD (Participant B) are also shown (Figure 4). The
median relative accumulated gEUD for the 10 participants was
95% of planned (range 83–109%).
Differences between accumulated and planned dose to particular
volumes of the rectum for the 10 participants are illustrated in
Figure 5. Differences in the volumes receiving particular doses
are also shown. For one participant (A), all DAs and volumes
were higher than planned. For four participants (B–E), all DAs
and volumes were lower than planned. For one participant (F),
all DAs and volumes were lower or the same as planned. For the
remaining four participants, some DAs and volumes were higher
and some lower than planned. Planned, accumulated and dif-
ference DSMs for Participant A are shown in Figure 2.
Figure 1. Graphical illustration of the rectum as a cylinder. The
cylinder was “cut” at the point where a vertical line from the
centroid of each contour crossed the posterior edge, and unfolded.
A, anterior; Inf, inferior; L, left; P, posterior; R, right; Sup, superior.
Figure 2. Planned dose–surface map (DSM) and accumulated DSM for Participant A. The difference DSM is also shown, where each
pixel from the planned DSM has been subtracted from the equivalent pixel from the accumulated DSM. The dose colour scale for
planned and accumulated DSMs is shown on the left and for the difference DSM is shown on the right. Differences in dose of up to
118.2Gy were seen, particularly to the posterior rectal wall. Where none of the megavoltage scans extended sufficiently inferior, the
relevant slices of rectum have been greyed out. A, anterior; Gy, Gray; Inf, inferior; L, left; P, posterior; R, right; Sup, superior.
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Difference DSMs for Participants B–E are shown in Figure 3. In
all four cases, some pixels received higher accumulated than
planned dose, despite DVHs showing that DAs and volumes
were lower than planned. The percentage of pixels receiving
higher accumulated than planned dose ranged from 27% (D) to
48% (E). The percentage of pixels receiving $5 Gy higher
accumulated than planned dose ranged from 1% (D) to 12% (C).
DISCUSSION
Late rectal toxicity occurs $90 days after RT and may include
bleeding, mucous, urgency, frequent loose bowel movements, pain
and incontinence.36 These morbidities can be severe and markedly
affect the quality of life.36 The cumulative incidence of $grade 2
toxicity, using the Radiation Therapy Oncology Group (RTOG)
scale, in the dose escalated arm of major randomized trials using
conformal RT, has been reported as between 18% and 35% with
a minimum median follow up of 5.3 years.7,8,10,11,41 With IMRT,
rates have been reported as between 6% and 26% with a mini-
mum median follow up of 2.4 years.13–15,27 Although these data
have yet to mature, they indicate that serious toxicity can affect
appreciable numbers of males.
Published DVH thresholds for toxicity of RTOG$grade 2 converge
at doses .70Gy, and volumes ,20%, suggesting that these values
are more consistently associated with toxicity.36 Five separate ﬁts of
the Lyman–Kutcher–Burman NTCP model to rectal toxicity data
have estimated similar parameters.42–46 The volume effect param-
eter tended to be small (,0.15), implying serial architecture, with
high-dose regions playing the predominant role in determining
toxicity risk.36 However, other work suggests that volumes re-
ceiving lower doses might also be contributory; a constraint for
incontinence of V40Gy ,65–70% has been suggested, for
example.37,47–51 This may be due to the volumes exposed to
intermediate doses playing a role in the recovery of tissue ex-
posed to high doses.52 Analysis of the RT01 trial has shown that
the number of DVH constraint points which are violated, and the
shape of the dose distribution, are correlated with outcome.51,53
These models use sample population data to predict the NTCP
for an individual based on their RT plan. If a group of patients
representative of the underlying population with identical plans
was investigated, the median toxicity expressed by the group
would be likely to reﬂect the NTCP. It is highly unlikely that the
toxicity expressed by each individual patient would be identical.
This is partly explained by variation in intrinsic patient factors
reported to inﬂuence late toxicity such as diabetes, haemor-
rhoids, inﬂammatory bowel disease, advanced age, androgen
deprivation therapy, rectum size, prior abdominal surgery and
severe acute rectal toxicity.36 There is also likely to be a genetic
component to the variation; this is an area of active research.54–56
The third factor to consider is the difference between the planned
DVH and what was actually delivered. This is crucial, as there is
Figure 3. Difference dose–surface maps (DSMs) for Participants B–E. In all four, some pixels received higher accumulated dose (DA)
than planned, despite their dose–volume histograms showing lower DAs and volumes. The percentage of pixels receiving higher DA
ranged from 27% (D) to 48% (E). The percentage of pixels receiving$5Gy higher dose than planned ranged from 1% (D) to 12% (C).
Where none of the megavoltage scans extended sufficiently inferior, the relevant slices of rectum have been greyed out. A, anterior;
Gy, Gray; Inf, inferior; L, left; P, posterior; R, right; Sup, superior.
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potential for monitoring delivered dose during treatment, and for
treatment adaptation if required. Minimizing variation in physical
dose would also contribute to greater understanding of the role of
intrinsic and genetic factors.
In line with the theory that the median toxicity expressed by
a group of patients with identical RT plans would equal that
predicted, we have shown that for our group of 10 patients, the
median position of the axial centre of the rectum over the 370
treatment fractions was within 1mm of its position at RT
planning.18 This suggests that at the population level, the RT
plan is a good surrogate for DA. However, considering the par-
ticipants individually, we found differences between accumu-
lated and planned gEUDs in all 10 cases. 1/10 had higher
accumulated than planned gEUD, in 6/10 cases accumulated
gEUD was lower than planned and in 3/10 the gEUDs were
within 1Gy of each other. In a group of 8 patients, Akino et al
found similar results, with higher accumulated than planned
gEUD in 1/8, lower in 6/8 and 1/8 within 1Gy.31
Consistent with this, we also found differences between accumu-
lated and planned DVHs for each of our 10 patients. Accumulated
V70Gy was higher than planned in one participant (A) and lower by
.2% in three participants (B, C and E) as shown in Figure 5.
Results were within 2% for the remaining six participants. This is in
contrast to previous work by Hatton et al,29 where 7/12 patients had
higher accumulated V70Gy than planned, 3/12 were lower and two
were similar. This difference may be due to the frequency of their
CT scans being twice a week, rather than daily, and also to their use
of cone-beam CT, which may be associated with dose recalculation
errors due to uncertainties in the HU values.29 3 out of our 10
participants (30%) had accumulated V65Gy.17%; this is similar to
the rate of 27% of scans seen in a study by Chen et al.19 Accu-
mulated D3% was higher than planned in one participant (A) and
Table 1. Comparison of planned and accumulated dose (DA) for
the 10 participants using generalized equivalent uniform dose
(gEUD). Dose differences (accumulated gEUD minus planned
gEUD) are also shown
Participant
gEUD (Gy)
Planned Accumulated Difference
A 56.9 62.2 5.3
B 60.3 50.1 210.2
C 58.8 55.8 23.0
D 53.3 47.3 26.0
E 57.1 50.2 26.9
F 57.3 53.8 23.6
G 60.3 61.3 1.1
H 56.4 55.0 21.4
I 56.0 53.6 22.4
J 60.8 61.1 0.3
Mean 22.7
Median 22.7
Figure 4. Dose–volume histograms (DVHs) for Participants A and B. The original planned DVHs for both participants were very
similar, with planned generalized equivalent uniform dose (gEUD) of 56.9Gy for A and 60.3Gy for B. However, the accumulated
gEUD for A was 62.2Gy (5.3Gy greater than planned) and for B was 50.1Gy (10.2Gy less than planned).
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lower by.2% in 6/10 participants as shown in Figure 5. In Akino’s
study, 0/8 patients had higher accumulated D2% and it was lower by
.2% in 5/8; these are similar to our results.31
The most extreme differences in accumulated V70Gy were for
Participants A and B. Accumulated V70Gy for Participant A was
13%, whereas the planned V70Gy had been only 3%. For Par-
ticipant B the reverse was seen; accumulated V70Gy was 1%,
whereas it was 9% at planning. As doses above this level are
more consistently associated with toxicity, we anticipate that
Participant A would be more likely to express toxicity than
suggested by their NTCP, and that Participant B would be less
likely to. If volumes receiving lower doses are also contributory
then perhaps Participant G, who received a V40Gy of 73% when
62% had been planned, might be more likely to display toxicity
than suggested by his NTCP. The converse would be true for
Participant E: planned V40Gy had been 48%, whereas actually the
accumulated V40Gy was 17%.
Summated DVHs suffer from a number of limitations when
considering DA. Even when the DVHs on 2 days show the same
volume receiving a given dose, the lack of spatial information in
a DVH means that these may correspond to different parts of the
rectum, meaning that these do not necessarily correspond to a true
DA DVH. Secondly, a DVH also cannot distinguish between the
rectal wall and the rectal contents. The use of rectal wall DSMs,
which preserve spatial information, avoids both these problems.
We have successfully implemented a method to generate planned,
accumulated and difference DSMs. By “cutting” the surface at
a point posterior of the centroid of each image, we ensured that
the central column of the DSM corresponded to the middle of the
anterior surface of the rectum. This is in contrast to the splitting
at the most posterior point of each outline as described by Murray
et al, which we found led to large variations from slice to slice.
All 10 participants had pixels on the difference DSM that were
.12Gy; these tended to be located superiorly and posteriorly.
This is not surprising, as these areas are away from the prostate,
the region where set-up is veriﬁed and is consistent with ﬁndings
from Murray et al.39 All 10 participants also had pixels on the
difference DSM that were ,2Gy; these tended to affect the an-
terior rectum. Further work is needed to extract the dose data
embedded in the DSMs; approaches that may be relevant include
mapping of dose to height and width parameters, eccentricity of
higher dose regions and regularity of isodose contours.53,57
Previous work with planned DSMs found that the risk of rectal
bleeding was higher for patients in whom .37.4% of the pixels
received at least 51Gy.53 None of our 10 participants exceeded this
threshold on the planned DSM; 2, however, did exceed it on the
accumulated DSM (A and J). Although this parameter could have
been predicted from the accumulated DVH for Participant A, it
would not have been detected for J (Figure 5). Increased bleeding
risk has also been found where the lateral extent of the 61Gy
isodose exceeded 59% of the circumference of the rectum.53 This
was the case for 4/10 of our Participants, A, E, F and J, and applied
to both planned and accumulated DSMs. This increased risk for E,
F and J would not have been identiﬁed from the DVHs. These
initial results support the notion that there is additional beneﬁt
from incorporating DSMs into dose-toxicity analyses.
A limitation of this work was the lack of availability of images
and contours for the most inferior part of the rectum, owing to
this being located away from the planning target volume and
Figure 5. Graphs showing absolute differences in dose (a) and volumes of rectum (b) between accumulated and planned
dose–volume histograms (DVHs) for the 10 participants. Doses to 80%, 70%, 65%, 60%, 55%, 50%, 40%, 30%, 25%, 15%, 5% and 3% of
the rectum are shown in (a) and volumes treated to 20, 30, 40, 50, 60, 65, 70 and 75Gy are shown in (b). For Participant A, all
accumulated doses and volumes were higher than planned. For Participants B–E, these were all lower than planned.
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therefore not scanned for image guidance purposes. Some data
were missing for 9/10 participants, with a median of four
missing slices per scan (6-mm slice thickness). Fortunately, this
part of the rectum is known to have little variation in size and
shape.21,58 Where shown, contouring of this area was challeng-
ing: the superior aspect of the pelvic muscles provided a level
below which the wall of the rectum could not be clearly seen on
the MV CT scans. We have previously investigated interobserver
contouring of this part of the rectum using deliberately extended
image guidance scans.59 We found that median Jaccard confor-
mity index above the superior pelvic muscles was 0.84, inter-
quartile range (IQR) 0.80–0.87. The corresponding value below
the muscles was 0.62, IQR 0.53–0.72. Using independent-
samples Kruskal–Wallis test, there was a signiﬁcant difference
between upper and lower portions of the rectum (p, 0.001).
We suggest that deforming the kV planning outlines onto the
MV scans is a pragmatic solution for obtaining lower rectal
contours. This will be our strategy in the future where MV slices
are unavailable for dose recalculation.
To test whether NTCP based on DA is more accurate than with
planned dose, large numbers of participants are required, with RT
planning, DA, and detailed late toxicity data. VoxTox has been set up
with this in mind, with anticipated recruitment of 1200 participants
treated for prostate cancer. We are developing automated software
for contouring and will assess the added value of incorporating voxel
tracking using a biomechanical modelling approach. Baseline data
will capture intrinsic patient factors and all participants will be of-
fered entry into the Radiogenomics: Assessment of Polymorphisms
for Predicting the Effects of Radiotherapy (RAPPER) study, which is
assessing polymorphisms for predicting the effects of RT.56 We plan
to develop NTCP models that incorporate DA as a co-variate in
addition to planned dose; in the future, intrinsic factors and radio-
genomics may become parameters to add to the model.
We propose that this strategy to calculate DA would enable more
accurate NTCP prediction for each individual undergoing RT
for prostate cancer. The delivered dose per pixel could be cal-
culated in real time, with updating of NTCP during the treat-
ment course. For those cases where accumulating dose is
suggestive of high NTCP, adaptive re-planning could be un-
dertaken to reduce this to normal levels. This approach would
have beneﬁted 1/10 of our participants; if our group is indeed
a good estimate of the population then re-planning 10% of
patients in clinical practice would be feasible. In cases, where the
rectal dose has already been planned to be as low as achievable
without compromising target volume coverage, the re-planning
could inform decisions on the costs and beneﬁts of reducing the
prescribed dose. Conversely, where low NTCP was anticipated,
there might be potential for safe dose escalation to tumour. 4/10
of our participants had lower accumulated dose-volumes than
those planned and potentially could have tolerated dose escala-
tion to tumour without increasing their NTCP.
CONCLUSION
Accumulated dose-volumes were different from those planned
in 10/10 participants, as measured by gEUD and constraints
from recent trials. DSMs provided information additional to the
DVH data: four participants had lower DAs and volumes than
planned, but each had pixels on the DSM that received $5Gy
more than was planned. Further work is needed to extract the
dose data embedded in the DSMs. These will be correlated with
toxicity as part of the VoxTox Programme.
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